Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind

livescience - A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called OTOF.

AI Summary: A gene therapy for inherited deafness delivered dramatic results, restoring hearing in roughly 90% of treated patients in the largest trial of its kind. Investigators report durable improvements over follow-up, signaling a potential one-time intervention for certain genetic deafness types and challenging the notion that auditory loss is always irreversible. Hope, meet hard data.


FDA approves first-ever gene therapy for inherited hearing loss

2 months / medicalxpress

2 months / livescience


Primate study finds human-like genetic cause of blindness

2 months / medicalxpress


Trial shows durable hearing restored in most patients

2 months / livescience

2 months / medicalxpress





Related Stories


Single‑infusion gene editing dramatically lowers LDL cholesterol in early trial / 5 wks

Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 2 months

Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 2 months

The peptide problem: Hype outruns evidence, researchers caution / 2 months

Researchers create world's first synthetic cell that grows and divides / 4 days

Stem cells show potent promise as a diabetes treatment / 6 wks

Mid‑stage Parkinson trial failure halts drug development plans / 7 wks

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Research Funding, Pancreatic Cancer, Price Transparency, Autism and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.